Catalog No.S1243 Synonyms: S20098
Molecular Weight(MW): 243.3
Agomelatine is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor.
Purity & Quality Control
Choose Selective 5-HT Receptor Inhibitors
|Description||Agomelatine is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor.|
Agomelatine completely normalizes stress-affected cell survival and partly reverses reduced doublecortin expression in the hippocampus of rats subjected to chronic footshock stress. 
|In vivo||Agomelatine is effective in reversing the transgenic mouse behavioural changes noted in the Porsolt forced swim test as well as in the elevated plus maze. Agomelatine also markedly accelerates readjustment of circadian cycles of temperature and activity following an induced phase shift.  Agomelatine enhances cell proliferation and neurogenesis in the ventral hippocampus (VH) of adult rats, a region pertinent to mood disorders. Agomelatine increases the ratio of mature vs immature neurons and enhances neurite outgrowth of granular cells in adult rats, suggesting an acceleration of maturation. Agomelatine also activates several cellular signals (extracellular signal-regulated kinase1/2, protein kinase B, and glycogen synthase kinase 3beta) known to be modulated by antidepressants and implicated in the control of proliferation/survival.  Agomelatine enhances the time devoted to active social interaction in unfamiliar pairs of rats exposed to a novel environment.  Agomelatine increases cell proliferation and neurogenesis in the ventral dentate gyrus of rats, a region notably implicated in response to emotion, which is consistent with the antidepressant-anxiolytic properties of Agomelatine. Agomelatine increases survival of newly formed neurons in the entire dentate gyrus of rats. |
-  Dagytė G, et al. Behav Brain Res, 2011, 218(1), 121-128.
-  Barden N, et al. Prog Neuropsychopharmacol Biol Psychiatry, 2005, 29(6), 908-916.
-  Soumier A, et al. Neuropsychopharmacology, 2009, 34(11), 2390-2403.
|In vitro||DMSO||48 mg/mL (197.28 mM)|
|Ethanol||48 mg/mL (197.28 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02374567||Terminated||Dementia|Depression|Schizophrenia|Psychosomatic Disorders|Anxiety Disorders||Hannover Medical School||January 2015||Phase 3|
|NCT01483053||Unknown status||Major Depressive Disorder (MDD)||Baker IDI Heart and Diabetes Institute|Servier Laboratories (Australia) Pty Ltd|The Alfred|Monash Medical Centre||January 2014||Phase 4|
|NCT01822418||Completed||Schizophrenia|Schizoaffective Disorder|Delusional Disorder||Central Institute of Mental Health Mannheim|Servier||January 2013||Phase 4|
|NCT01488071||Completed||Major Depressive Disorder||H. Lundbeck A/S||January 2012||Phase 3|
|NCT01731899||Completed||Major Depression|Fibromyalgia||Universidad de Granada||June 2010||--|
|NCT01108393||Completed||Obsessive Compulsive Disorder||Servier||May 2010||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.